| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells (NCT04911478) | Adicet Therapeutics | 2022-02-14 |
| Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma (NCT05155215) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2021-12-31 |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (NCT05024045) | Eli Lilly and Company | 2021-09-30 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (NCT04849416) | Eli Lilly and Company | 2021-05-14 |
| Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (NCT04662255) | Loxo Oncology, Inc. | 2021-04-08 |
| A Phase 1 Study of ADI-001 in B Cell Malignancies (NCT04735471) | Adicet Therapeutics | 2021-03-04 |
| A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea (NCT04036448) | Celgene | 2019-11-28 |
| A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion (NCT03190330) | Johnson & Johnson Private Limited | 2019-06-26 |
| A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma (NCT03647124) | Celgene | 2019-03-13 |
| Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma (NCT03682796) | Triphase Research and Development III Corp. | 2018-10-15 |
| Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL (NCT03567876) | Fondazione Italiana Linfomi - ETS | 2018-09-03 |
| Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India (NCT03476655) | Johnson & Johnson Private Limited | 2018-04-28 |
| Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants (NCT03053024) | Xian-Janssen Pharmaceutical Ltd. | 2017-04-14 |
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (NCT02972840) | Acerta Pharma BV | 2017-04-05 |
| Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (NCT02743546) | Janssen Research & Development, LLC | 2016-07-20 |
| A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (NCT03425591) | Janssen-Cilag Ltd. | 2016-05-11 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) (NCT02669017) | ADC Therapeutics S.A. | 2016-03-01 |
| An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma (NCT02413489) | Janssen Research & Development, LLC | 2015-09-02 |
| Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) (NCT02455297) | Bayer | 2015-08-24 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment (NCT02341781) | Celgene | 2015-04-01 |
| Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL (NCT02419560) | Craig Portell, MD | 2015-04-01 |
| A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) (NCT02278796) | Insel Gruppe AG, University Hospital Bern | 2015-04-01 |
| Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (NCT02169180) | Janssen Pharmaceutical K.K. | 2014-08-01 |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma (NCT01786135) | Seagen Inc. | 2013-02-01 |
| A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers (NCT01117142) | National Heart, Lung, and Blood Institute (NHLBI) | 2010-06-03 |
| Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL (NCT00490529) | Ronald Levy | 2009-08-01 |
| Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma (NCT00992134) | St. Bortolo Hospital | 2009-06-01 |
| A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (NCT00875667) | Celgene | 2009-04-30 |
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies (NCT00861510) | National Heart, Lung, and Blood Institute (NHLBI) | 2009-03-05 |
| SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) (NCT00871546) | Merck Sharp & Dohme LLC | 2009-03-01 |
| Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (NCT00700258) | Pfizer | 2008-02-13 |
| EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma (NCT00114738) | National Cancer Institute (NCI) | 2005-06-15 |
| Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma (NCT00261612) | Medical University of Vienna | 2005-01-01 |
| Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL (NCT00209222) | European Mantle Cell Lymphoma Network | 2004-07-01 |
| Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL (NCT00209209) | European Mantle Cell Lymphoma Network | 2004-01-14 |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies (NCT00514722) | University of California, San Francisco | 2002-10-01 |
| Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma (NCT00038623) | M.D. Anderson Cancer Center | 2002-04-01 |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma (NCT00992992) | GlaxoSmithKline | 2001-06-28 |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS (NCT00025662) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-05-01 |
| Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (NCT00005780) | National Cancer Institute (NCI) | 2000-06-01 |